Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1998 1
2007 1
2008 1
2009 3
2010 1
2011 2
2015 3
2016 2
2018 1
2019 3
2020 2
2021 2
2022 3
2023 6
2024 5
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D, Bedossa P, Geier A, Francque S, Allison M, Papatheodoridis G, Cortez-Pinto H, Pais R, Dufour JF, Leeming DJ, Harrison SA, Chen Y, Cobbold JF, Pavlides M, Holleboom AG, Yki-Jarvinen H, Crespo J, Karsdal M, Ostroff R, Zafarmand MH, Torstenson R, Duffin K, Yunis C, Brass C, Ekstedt M, Aithal GP, Schattenberg JM, Bugianesi E, Romero-Gomez M, Ratziu V, Anstee QM, Bossuyt PM; Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators. Vali Y, et al. Lancet Gastroenterol Hepatol. 2023 Aug;8(8):714-725. doi: 10.1016/S2468-1253(23)00017-1. Epub 2023 Mar 21. Lancet Gastroenterol Hepatol. 2023. PMID: 36958367 Free article.
Adults (aged 18 years) with paired liver biopsy and serum samples were eligible; those with excessive alcohol consumption or evidence of other chronic liver diseases were excluded. ...FINDINGS: Of 1430 participants with NAFLD in the LITMUS metacohort with serum samp …
Adults (aged 18 years) with paired liver biopsy and serum samples were eligible; those with excessive alcohol consumption or evidence …
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Sanyal AJ, et al. Hepatology. 2022 May;75(5):1235-1246. doi: 10.1002/hep.32204. Epub 2022 Feb 7. Hepatology. 2022. PMID: 34662449 Free PMC article. Clinical Trial.
Liver fibrosis at baseline and week 48 (W48) was staged by NASH Clinical Research Network (CRN) and Ishak classifications and a machine learning (ML) approach, hepatic collagen and alpha-smooth muscle actin (alpha-SMA) expression were quantified by morphometry, liver stiffness (L …
Liver fibrosis at baseline and week 48 (W48) was staged by NASH Clinical Research Network (CRN) and Ishak classifications and a machine lear …
Metabolomics Profiling of Epicardial Adipose Tissue: MESA and the Rotterdam Study.
Neeland IJ, Zhu F, Graca G, Lymperopoulos A, Iacobellis G, Farzaneh A, Bos D, Ghanbari M, Goldberger JJ, Kavousi M, Greenland P. Neeland IJ, et al. J Am Heart Assoc. 2025 Jul;14(13):e039750. doi: 10.1161/JAHA.124.039750. Epub 2025 Jun 18. J Am Heart Assoc. 2025. PMID: 40530511 Free PMC article.
METHODS: Untargeted 1H nuclear magnetic resonance metabolomics profiling of serum was performed (1-dimensional nuclear magnetic resonance, Carr-Purcell-Meiboom-Gill Echo Train Acquisition, lipidomics) and EAT was measured with computed tomography in MESA (Multi-Ethnic Stud …
METHODS: Untargeted 1H nuclear magnetic resonance metabolomics profiling of serum was performed (1-dimensional nuclear magnetic reson …
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
Sanyal AJ, Ling L, Beuers U, DePaoli AM, Lieu HD, Harrison SA, Hirschfield GM. Sanyal AJ, et al. JHEP Rep. 2021 Feb 19;3(3):100255. doi: 10.1016/j.jhepr.2021.100255. eCollection 2021 Jun. JHEP Rep. 2021. PMID: 33898959 Free PMC article.
BACKGROUND & AIMS: Higher serum bile acid levels are associated with an increased risk of cirrhosis and liver-related morbidity and mortality. ...RESULTS: Treatment with aldafermin resulted in significant dose-dependent reductions in serum bile acids. In particu …
BACKGROUND & AIMS: Higher serum bile acid levels are associated with an increased risk of cirrhosis and liver-related morbidity a …
Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.
Panagiotopoulos N, Wolfson T, Harris DT, Batakis D, Agni R, Ceriani L, Covarrubias Y, Hamilton G, Middleton MS, Martins VF, Gamst AC, Oechtering TH, Sappenfield R, Horgan S, Grunvald E, Funk LM, Jacobsen GR, Lidor AO, Goodman JA, Khoury SB, Sirlin CB, Reeder SB. Panagiotopoulos N, et al. Hepatology. 2026 Jan 1;83(1):127-141. doi: 10.1097/HEP.0000000000001318. Epub 2025 Mar 25. Hepatology. 2026. PMID: 40132140
APPROACH AND RESULTS: PDFF was evaluated alone and with other potential classifiers (imaging, serum and anthropometric), using Bayesian Information Criterion-based stepwise logistic regression models. ...
APPROACH AND RESULTS: PDFF was evaluated alone and with other potential classifiers (imaging, serum and anthropometric), using Bayesi …
Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial.
Ghanei M, Ghalebaghi B, Sami R, Torabizadeh M, Mirsadraee M, Amra B, Tavakol M, Raji H, Fallahpour M, Kiani A, Abedini A, Jabbari Azad F, Mahdaviani SA, Attaran D, Samet M, Tavana S, Haddadzadeh Shoushtari M, Nazari J, AghaeiMeybodi F, Fazlollahi MR, Ghasemi R, Sabzvari A, Kafi H, Idani E. Ghanei M, et al. Front Immunol. 2024 Jul 29;15:1425906. doi: 10.3389/fimmu.2024.1425906. eCollection 2024. Front Immunol. 2024. PMID: 39136011 Free PMC article. Clinical Trial.
Each subject received either medication with a dose ranging from 150 to 375 mg based on pre-treatment serum total IgE level (IU/mL) and body weight (kg) every two or four weeks for a duration of 28 weeks. ...
Each subject received either medication with a dose ranging from 150 to 375 mg based on pre-treatment serum total IgE level (IU/mL) a …
Randomized placebo-controlled trial of losartan for pediatric NAFLD.
Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P, Jain AK, Karpen SJ, Lavine JE, Mohammad S, Miriel LA, Molleston JP, Mouzaki M, Sanyal A, Sharkey EP, Schwimmer JB, Tonascia J, Wilson LA, Xanthakos SA; NASH Clinical Research Network. Vos MB, et al. Hepatology. 2022 Aug;76(2):429-444. doi: 10.1002/hep.32403. Epub 2022 Feb 28. Hepatology. 2022. PMID: 35133671 Free PMC article. Clinical Trial.
Inclusion criteria were age 8-17 years, histologic NAFLD activity score 3, and serum alanine aminotransferase (ALT) 50 U/l. Children received 100 mg of losartan or placebo orally once daily for 24 weeks. ...
Inclusion criteria were age 8-17 years, histologic NAFLD activity score 3, and serum alanine aminotransferase (ALT) 50 U/l. Children …
Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis.
Hu K, Perez-Matos MC, Argemi J, Vilar-Gomez E, Shalaurova I, Bullitt E, Landeen L, Sugahara G, Deng H, Mathur K, Tran S, Cai H, He H, Yalcin Y, Vieira Barbosa J, Ventura-Cots M, Marx K, Gad AP, Niezen S, Izunza Barba S, Ang LH, Popov YV, Fricker Z, Lai M, Curry M, Afdhal N, Szabo G, Mukamal KJ, Sanyal AJ, Otvos JD, Malik R, Saito T, Connelly MA, Chalasani NP, Bataller R, Jiang ZG. Hu K, et al. Hepatology. 2022 Apr;75(4):968-982. doi: 10.1002/hep.32203. Epub 2021 Dec 7. Hepatology. 2022. PMID: 34662439 Free PMC article.
This study aims to define the diagnostic value of LP-Z in alcohol-associated hepatitis (AH) and interrogate the biology behind its formation. APPROACH AND RESULTS: We measured serum levels of LP-Z using nuclear magnetic resonance spectroscopy, a well-established clinical a …
This study aims to define the diagnostic value of LP-Z in alcohol-associated hepatitis (AH) and interrogate the biology behind its formation …
Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients.
Siddiqui MS, Parmar D, Shaikh F, Forsgren M, Patel S, Bui AT, Boyett S, Patel V, Sanyal AJ. Siddiqui MS, et al. Liver Transpl. 2023 Sep 1;29(9):979-986. doi: 10.1097/LVT.0000000000000110. Epub 2023 Feb 28. Liver Transpl. 2023. PMID: 36847136
A relative 30% reduction from baseline MRI-PDFF value was noted in 47% of all patients and 63% of patients with baseline MRI-PDFF >5%. Reduction in serum alkaline phosphatase was an independent predictor of MRI-PDFF response. Saroglitazar did not decrease fat-free muscl …
A relative 30% reduction from baseline MRI-PDFF value was noted in 47% of all patients and 63% of patients with baseline MRI-PDFF >5%. Re …
37 results